South Africa’s HIV Prevention Efforts Advance with Lenacapavir Rollout ### DATELINE: Johannesburg, South Africa – June 26, 2026 In a groundbreaking advancement in the fight against HIV/AIDS, South Africa embarked on a new chapter with the introduction of lenacapavir, a long-acting injectable that promises to revolutionize HIV prevention efforts.
The landmark event was marked by the first administration of the injectable to 21-year-old Jane Mndebele in Mpumalanga province, a momentous occasion celebrated by President Cyril Ramaphosa and Health Minister Dr. Aaron Motsoaledi.
Lenacapavir, a twice — yearly antiretroviral injection, has shown near-total efficacy in clinical trials, offering a significant shift from the daily oral medications that have been the norm until now.
This innovative approach to HIV prevention is particularly relevant in South Africa, which bears a substantial HIV burden, with 8. 15 million people living with the virus as of 2025, representing 12.
9% of the total population.
Jane Mndebele’s excitement at receiving the injection was a reflection of the optimism surrounding this new HIV prevention method. “I am excited, “she said after the injection was administered by Health Minister Motsoaledi himself.
The event at the Lilian Ngoyi Stadium in Secunda, Mpumalanga, was a testament to the collaborative efforts between the government, civil society, and private sector to combat the disease. Prof. Nicholas Crisp, an expert in global health, described lenacapavir as a “game-changer. “.
He emphasized its potential to shift HIV prevention from daily routines to a more manageable schedule, which could significantly improve adherence rates and overall health outcomes.
The South African National AIDS Council (SANAC) and the National Department of Health (NDoH) have taken a proactive approach to the implementation of lenacapavir.
A National Roundtable on Lenacapavir Access and Sustainability was convened, bringing together stakeholders from across the spectrum to ensure the successful introduction and sustainability of the new prevention method.
Despite the optimism, several questions remain unanswered.
The long — term effects of lenacapavir on individuals who receive it are yet to be fully understood.
Additionally, the impact of the new injectable on existing HIV prevention and treatment programs in South Africa is a subject of ongoing scrutiny.
The cost of lenacapavir and its funding mechanism are also critical issues.
As South Africa continues to grapple with the economic implications of the pandemic, ensuring affordable access to this new prevention tool is a priority.
The World Health Organization (WHO) has applauded South Africa’s leadership in advancing HIV prevention through the rollout of lenacapavir.
The introduction of the twice — yearly injectable pre-exposure prophylaxis (PrEP) option demonstrates South Africa’s commitment to expanding access to effective, people-centred prevention options.
As the nation awaits further data on the efficacy and safety of lenacapavir, there is a collective hope that this new tool will contribute to the reduction of new HIV infections and bring South Africa closer to ending AIDS as a public health threat by 2030.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Google News v2
